
Icro Meattini/X
May 6, 2025, 10:05
Icro Meattini: Breast-Conserving Therapy is safe and effective for BRCA1/2 carriers
Icro Meattini, Associate Professor of Radiation Oncology at the University of Florence, shared a post on X:
“Breast-Conserving Therapy is safe & effective for BRCA1/2 carriers—no impact on OS or DMFS.
CBC risk (esp. in BRCA1) supports considering bilateral mastectomy.
Personalised decisions, early BRCA testing & expert counselling are key.”
Icro Meattini emphasized that breast-conserving therapy is a safe and effective option for BRCA1 and BRCA2 carriers, with no effect on overall or distant metastasis-free survival.
He also noted the importance of considering bilateral mastectomy, particularly in BRCA1 cases, and highlighted the role of early BRCA testing and personalized counseling.
More posts featuring Icro Meattini.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 6, 2025, 10:37
May 6, 2025, 10:33
May 6, 2025, 10:31
May 6, 2025, 10:19
May 6, 2025, 10:13